Sign Out
No evidence exists that indicated that treatment with Eprex alters the metabolism of other drugs. Drugs that decrease erythropoiesis may decrease the response to Eprex.
Since cyclosporin is bound by red blood cells there is potential for a drug interaction. If Eprex is given concomitantly with cyclosporin, blood levels of cyclosporin should be monitored and the dose of cyclosporin adjusted as the hematocrit rises.
No evidence exists that indicated an interaction between Eprex and G-CSF or GM-CSF with regard to hematological differentiation or proliferation of tumor cells from biopsy specimens in vitro.
The effect of Eprex may be potentiated by the simultaneous therapeutic administration of a hematinic agent, such as ferrous sulphate, when a deficiency state exists.
In patients with metastatic breast cancer, subcutaneous co-administration of 40,000 IU/mL Eprex with trastuzumab (6 mg/kg) had no effect on the pharmacokinetics of trastuzumab.
